SHARE Continuous processing based on artificial intelligence, robotics and data science hasn’t been adopted in the pharma and biotech manufacturing verticals yet, says a disruptor business. While the data-science side of things, such as data collection, and the formatting of the figures to make the numbers useful has been approached by innovators, the smart manufacturing-oriented digital transformations aren’t there, according to John Vitalie (pictured), chief executive officer at AI firm Aizon. “Leveraging machine learning and artificial intelligence in the manufacturing process” produces higher yields and predictability, and ultimately better outcomes for patients, though, Vitalie explained, so there should be a focus on it. Newer tech would also benefit, such as precision or personalized medicine, which needs small, or micro-level batch manufacturing.